ABBV vs HSIC
By Alex · Tickerpine
AbbVie Inc. vs Henry Schein, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | HSIC |
|---|---|---|
| Price | $295.03 | $86.22 |
| Market cap | $521.50B | $9.53B |
| P/E ratio | 50.7 | 23.6 |
| ROE | — | 9.20% |
| Profit margin | 15.67% | 3.07% |
| Revenue growth | 10.30% | 4.00% |
| Dividend yield | 2.35% | 0.00% |
| Beta | 0.19 | 0.86 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs HSIC in plain English
- ABBV is the bigger company — about 54.7× the market cap of HSIC.
- HSIC is cheaper on earnings (P/E 23.6 vs 50.7).
- ABBV is growing revenue faster (10% vs 4%).
- ABBV pays a dividend (2.35%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
HSIC return calculator
See what $1,000 in Henry Schein, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.